Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs) which are designed to maximize the therapeutic benefit for cancer patients.
Crossfire was founded in 2021 and is developing therapeutics for the targeting of cancer associated kinases, from every angle.
Rogier Buijsman, CEO of Crossfire states: ‘”The Marie Curie building stands as a beautiful modern structure featuring state-of-the-art laboratories. I’m looking forward to seeing all the new discoveries that will come from this new facility in the future!”
